Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Innovation Action · Running

DECIPHER Decentralized microfluidic in vitro diagnostic patch for pandemic control

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€6.9m
Total cost
€7.1m
Partners
11 organisations in 6 countries
Type
Innovation Action
Grant agreement
101137242

What the project is doing

In the project's own words, from its summary on CORDIS.

In vitro diagnostic (IVD) technologies have revolutionized healthcare, yet remain confined to the laboratories. This traditional approach massively failed to manage viral outbreak during the COVID-19 pandemic because it lacked quick and cost-effective diagnosis. Moreover, an urgent need was evident for bringing quantitative lab-quality diagnosis to the hands of end users (i.e., point-of-care, POC). Despite high expectations from Lab-on-Chip technologies, they failed so far to disrupt the IVD market due to their complexity, high cost, off-chip sample preparation, poor scalability, to mention a few.

The DECIPHER consortium aims to revolutionize the POC IVD field by developing innovative microfluidic-based DECIPHER patch capable of both biofluids (self-)sampling via hollow microneedles (HMNs) and immediate analysis of this sample on the very same patch in a completely self-powered manner, producing quantitative result to be read out with a re-purposed glucose meter. Ebola and Lassa viruses are selected as relevant model systems because they are highly contagious with human-to-human transmission, high mortality rate and no vaccine/treatment available, thus having meaningful potential for new pandemic threats.

To offer such a genuine sample-to-result quantitative POC solution, the DECIPHER value chain, from lab to market, will cover: (1) investigation of high-throughput manufacturing processes with (2) novel polymers, innovations in the fields of (3) microfluidics, (4) HMNs and (5) quantitative molecular bioassays, (6) DECIPHER patch analytical and clinical validation (both retrospective and prospective), as well as (7) AI-based models, (8) socio-economic/systems analysis and (9) life cycle assessment of DECIPHER patch.

This true interdisciplinarity will be represented by highly experienced DECIPHER consortium with partners from 3 universities, 5 research institutes, 1 SME, 1 large company and 1 non-governmental organization from 6 countries.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Joanneum Research Forschungsgesellschaft MbhGrazAustriaParticipant
Montanuniversitaet LeobenLeobenAustriaParticipant
Polymer Competence Center Leoben GmbHLeobenAustriaParticipant
Epcon BVAntwerpBelgiumParticipant
Instituut Voor Tropische GeneeskundeAntwerpenBelgiumParticipant
Médecins sans Frontières BelgiumBruxelles / BrusselBelgiumAssociatedpartner
Institut National De Recherche Biomedicale Du ZaireKinshasa GombeCDParticipant
Temicon GmbHDortmundGermanyParticipant
Centre National De Formation Et De Recherche En Sante Rurale De MaferinyahForecariahGNParticipant
Carnegie Mellon UniversityPittsburghUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI